Assignee
IGM BIOSCIENCES INC
US·21 granted patents·32 pending applications·198 citations·filing 2013–2023
Top patents by PatentIndex Score
53 records- 0198US10975147B2Modified J-chainIGM BIOSCIENCES INC·Filed 2020·Granted Apr 13, 2021·8 cites·28 claims
- 0298US10400038B2Modified J-chainIGM BIOSCIENCES INC·Filed 2015·Granted Sep 3, 2019·21 cites·21 claims
- 0398US9951134B2Modified J-chainIGM BIOSCIENCES INC·Filed 2017·Granted Apr 24, 2018·25 cites·23 claims
- 0497US11542342B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2020·Granted Jan 3, 2023·4 cites·27 claims
- 0597US11192941B2Multi-valent human immunodeficiency virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Granted Dec 7, 2021·4 cites·20 claims
- 0697US10618978B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2016·Granted Apr 14, 2020·16 cites·7 claims
- 0796US10954302B2Anti-PD-L1 antibodiesIGM BIOSCIENCES INC·Filed 2017·Granted Mar 23, 2021·10 cites·19 claims
- 0896US10899835B2IgM Fc and J-chain mutations that affect IgM serum half-lifeIGM BIOSCIENCES INC·Filed 2020·Granted Jan 26, 2021·7 cites·28 claims
- 0994US10787520B2Multimeric bispecific binding molecules specific for CD20 and CD3IGM BIOSCIENCES INC·Filed 2016·Granted Sep 29, 2020·13 cites·31 claims
- 1093US10604559B2Multi-valent hepatitis B virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Mar 31, 2020·15 cites·18 claims
- 1193US9458241B2Antibody induced cell membrane woundingIGM BIOSCIENCES INC·Filed 2013·Granted Oct 4, 2016·21 cites·20 claims
- 1291US10689449B2Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Jun 23, 2020·12 cites·30 claims
- 1391US10351631B2Constant chain modified bispecific, penta- and hexavalent Ig-M antibodiesIGM BIOSCIENCES INC·Filed 2014·Granted Jul 16, 2019·18 cites·22 claims
- 1490US11535664B2Multi-valent hepatitis B virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Granted Dec 27, 2022·2 cites·19 claims
- 1590US11401337B2Modified human IgM constant regions for modulation of complement-dependent cytolysis effector functionIGM BIOSCIENCES INC·Filed 2018·Granted Aug 2, 2022·6 cites·36 claims
- 1689US10570191B2Multi-valent human immunodeficiency virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Feb 25, 2020·7 cites·14 claims
- 1788US11639389B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2016·Granted May 2, 2023·4 cites·14 claims
- 1888US11555075B2Modified J-chainIGM BIOSCIENCES INC·Filed 2018·Granted Jan 17, 2023·2 cites·46 claims
- 1983US11578131B2Polynucleotides encoding death domain-containing receptor-5 (DR5) binding moleculesIGM BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·23 claims
- 2081US12486336B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 2181US2023279111A1Modified j-chainIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2280US2024002514A1Anti-pd-l1 antibodiesIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2379US10822399B2IgA multi-specific binding moleculesIGM BIOSCIENCES INC·Filed 2015·Granted Nov 3, 2020·2 cites·17 claims
- 2479US2024124584A1Igm fc and j-chain mutations that affect igm serum half-lifeIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2578US2023203173A1Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2669US2022403009A1Multimeric coronavirus binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2768US2026070999A1Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodiesIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2868US2021163600A1Anti-pd-l1 antibodiesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2967US2022340676A1Modified human igm constant regions for modulation of complement-dependent cytolysis effector functionIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3067US2022177595A1Multimeric gitr binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3166US2021087273A1IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFEIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3266US2022169751A1Multimeric ox40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3364US2023058162A1Multimeric coronavirus binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3464US2022106399A1Multimeric cd40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3563US2025051473A1Anti-cd38 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3663US2021388098A1Multimeric cd137/4-1bb binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3760US2024076392A1Anti-cd123 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3859US2021032357A1Cd20 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3955US2024002526A1Uses of effector cell engaging molecules with moieties of differing potenciesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4054US2022372142A1Multimeric antibodies with enhanced selectivity for cells with high target densityIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4154US2022289856A1Multimeric bispecific anti-cd123 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4253US2023073926A1Highly sialylated multimeric binding moleculesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4352US2022106398A1Anti-gitr antigen-binding domains and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4452US2022306760A1Igm glycovariantsIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4551US2023174660A1Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancerIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4651US2019338040A1Multimeric cd137/4-1bb binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4751US2019338041A1Multimeric cd40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4851US2019330360A1Multimeric gitr binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4950US2021380701A1MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULESIGM BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 5050US2020392239A1Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancerIGM BIOSCIENCES INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →